Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide- responsive and - resistant glioblastoma

摘要

Background. The survival rate for patients with glioblastoma (GBM) remains dismal. New therapies targeting molecular pathways dysregulated in GBM are needed. One such clinical-stage drug candidate, CBL0137, is a curaxin, small molecules which simultaneously downregulate nuclear factor-kappaB (NF-kappa B) and activate p53 by inactivating the chromatin remodeling complex, Facilitates Chromatin Transcription (FACT).